Abstract
Our case highlights SARS-CoV-2 and pembrolizumab as trigger of secondary hemophagocytic lymphohistiocytosis. Although it is a rare complication, it must be suspected in order to start specific treatment. In this context, intravenous immunoglobulins could be a therapeutic option.
Author supplied keywords
Cite
CITATION STYLE
APA
Ramos-Ruperto, L., Busca-Arenzana, C., Valdivieso, J., López-Granados, E., & Robles-Marhuenda, Á. (2021). COVID-19 and Pembrolizumab-Induced Secondary Hemophagocytic Lymphohistiocytosis: a Case Report. SN Comprehensive Clinical Medicine, 3(6), 1412–1415. https://doi.org/10.1007/s42399-021-00882-8
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free